Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals' Notes Payables history runs 3 years deep, the most recent figure standing at $3.0 million for Q4 2023.

• In Q4 2023, Notes Payables changed 0.0% year-over-year to $3.0 million; the TTM figure through Dec 2023 stood at $3.0 million (changed 0.0% YoY), while the FY2023 annual figure was $3.0 million, changed 0.0% from the prior year.
• Notes Payables was $3.0 million for Q4 2023 at Indivior Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $3.0 million in Q4 2021 to a low of $3.0 million in Q4 2021.
• Historically, Notes Payables has averaged $3.0 million across 3 years, with a median of $3.0 million in 2021.
• Biggest YoY gain for Notes Payables was 0.0% in 2022; the steepest drop was 0.0% in 2022.
• A 3-year view of Notes Payables shows it stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
• The last three Notes Payables figures came in at $3.0 million (Q4 2023), $3.0 million (Q4 2022), and $3.0 million (Q4 2021), per Business Quant data.